Morgan Stanley raised the firm's price target on Amwell to $6.50 from $6 and keeps an Equal Weight rating on the shares. Revenue upside in the quarter and tighter cost controls "mark a solid start to the year, admittedly against low investor expectations," the analyst says in a post-earnings note.
